DOAC in intermediate-high risk PE

The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-high risk pulmonary embolism (PE) are unknown. The aims of the present study were to describe outcomes of patients receiving early apixaban or rivaroxaban prescription rather the recommended delayed prescription strategy.

Source: Thrombosis Research - October 7, 2020 Category: Hematology Authors: Romain Chopard, Marc Badoz, Charly Eveno, Fiona Ecarnot, Nicolas Falvo, Elsa Kalbacher, Gilles Capellier, Benoit Guillon, Fran çois Schiele, Nicolas Meneveau Source Type: research